The acquisition culminates a year-long collaborative research agreement between VDDI and ILB that established the proof of principle for the technology for use in human and animal infectious diseases.
Everett, ILB's chief scientific officer, can become a member of the scientific advisory board of VDDI, as well as remain an active consultant to the medical peptide project.
VDDI Pharmaceuticals is a pharmaceutical development company formed to in-license and develop therapeutic indications in the areas of infectious disease, cancer and cardiovascular disease.
Under the terms of the agreement, ILB will provide VDDI with access to ILB's patents and extensive know-how related to peptides with increased stability to degradation by proteases.
We are very pleased to have VDDI as a drug development partner," said Nicholas P.
VDDI Pharmaceuticals is a pharmaceutical development company formed to in-license and develop therapeutics indications in the areas of infectious disease, cancer, and cardiovascular disease.
In collaboration with PPD Discovery, and The University of Alabama, VDDI has developed a preclinical and clinical strategy in accordance with these new regulations, and will discuss this strategy with the FDA at a pre-IND meeting to be scheduled.
VDDI will use the HHS Small Business Innovation Research Grant to develop a NADs inhibitor.